RICHLAND, Wash.--(BUSINESS WIRE)--Noted medical researchers from around the country will gather at the 26th annual American Association of Physicists in Medicine (AAPM) conference in Minneapolis, MN, July 22-26, to present results of their studies focusing on Proxcelan™ with Cesium-131. The abstracts illustrate the radiobiological characteristics and related dosimetric outcomes in treatment planning using Proxcelan™ with Cesium-131 -- the newest isotope used in brachytherapy for the treatment of prostate cancer and the first breakthrough in more than 20 years.
